Chronic Disease Management Service Opportunities for Community Pharmacists During the COVID-19 Pandemic

Gregory Dwyer, MPH; Adebola Popoola, JD, MPH, MBS; Naomi Seiler, JD; Nicole Therrien, PharmD, MPH; Aaron Karacuschansky, MPH; Erika Fulmer, MHA; Katie Horton, JD, RN, MPH


Prev Chronic Dis. 2022;19(3):e10 

In This Article


To understand the extent to which pharmacists are and could be used to provide services for chronic disease, academic researchers working with the Centers for Disease Control and Prevention's Division for Heart Disease and Stroke Prevention interviewed pharmacists and chronic disease experts during nine 1-hour video interviews in June and July 2020. Interviewees represented 10 organizations in pharmacy policy and practice, including independent pharmacies, pharmacy chains, state boards of pharmacy, community pharmacists, and health-system pharmacists. Researchers also interviewed representatives of the American Heart Association.

Using an interview guide, researchers conducted semistructured interviews that explored opportunities and barriers for community pharmacist provision of chronic disease management services before, during, and after the COVID-19 pandemic. Chronic disease management services, including medication reconciliation, chronic disease education and counseling, and medication management services (eg, medication therapy management and comprehensive medication management), were discussed.

Researchers reviewed transcripts of the interviews, identified key themes across multiple interviews as well as novel responses of interest, and developed a white paper describing 21 key findings from the interviews. All interviewees were given the opportunity to review the draft white paper to ensure that their comments were appropriately reflected. This article summarizes several novel findings from the white paper. Office on Management and Budget and institutional review board approvals were determined unnecessary and exempt, respectively.